DiaMedica Therapeutics Inc.

DMAC ·Healthcare, Drug Manufacturers - General, United States
Financial Statements Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2017
Operating Activities
Net Income $-4.3M
Depreciation & Amortization
Depreciation $4.0K
Amortization
Stock-Based Compensation $409.0K
Net Cash from Operating Activities $-3.9M
Investing Activities
Capital Expenditures $22.0K
Business Acquisitions
Net Cash from Investing Activities $-22.0K
Financing Activities
Dividends Paid
Stock Repurchases
Net Cash from Financing Activities $3.5M
Net Change in Cash $-383.0K
Free Cash Flow $-3.9M
← Newer Page 2 of 2 Older →